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ABSTRACT 
 
Purpose: The authors’ objectives were to compare height at diagnosis of children with 
bone tumors with that of Spanish reference children; to analyze the frequency of the 
genotypes for the polymorphisms of the vitamin D receptor (VDR), estrogen receptor 
(ER), and collagen Iα1  (COLIα1) genes in patients and in healthy controls; and to test 
the relationship between the genetic markers and height. 
 
Patients and Methods: Height and weight at diagnosis were measured in 58 
osteosarcoma and 36 Ewing sarcoma patients and compared with standards published 
for Spanish reference children according to sex and age. For the molecular analysis, 
genetic polymorphisms of the VDR (Fok I, Apa I, and TaqI), ER (Pvu II and XbaI), and 
COLIα1  (Msc I) genes were characterized in 72 osteosarcoma and 53 Ewing sarcomas 
and in a group of 143 healthy matched children. 
 
Results: Osteosarcoma and Ewing sarcoma patients were significantly taller than 
Spanish reference children. Osteosarcoma patients showed a significantly higher 
frequency of the Ff genotype for the Fok I polymorphism (VDR gene) than the control 
group. The odds ratio for this genotype was 1.78, with an increased relative risk of 78% 
for heterozygous Ff carriers. Among Ewing sarcoma patients, this same genotype was 
significantly associated with lower height than homozygotes (FF or ff). 
 
Conclusions: Children with bone cancer are significantly taller than the reference 
population, which may be influenced by the genotype for the Fok I polymorphism of the 
VDR gene. 
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INTRODUCTION 
 
Malignant bone tumors account for 4% to 6% of all cancers that occur during infancy 
and adolescence in most European countries. The age-standardized rate ranges from 4.5 
to 7.5 per million.1 Within the group of childhood bone tumors, two main histologic 
subtypes can be distinguished: osteosarcoma, which accounts for 50% of the cases, and 
Ewing sarcoma (including primitive neuroectodermal tumors of bone), which accounts 
for 40% to 45% of the cases.2 
 
Since the 1950s, several clinical and epidemiologic studies have suggested a link 
between the acceleration of skeletal growth that occurs during infancy and adolescence, 
and the development of bone tumors. First, the rates of incidence and mortality due to 
these tumors show a progressive increase during the two first decades of life, peaking in 
adolescence, similar to the growth pattern.1,2 The age at diagnosis of most 
osteosarcomas overlaps with the pubertal growth spurt and with maximal reconstructive 
activity within the bone cortex. Second, the age of presentation is sex-dependent: girls 
are diagnosed at earlier ages, in good agreement with the earlier presentation of the 
growth spurt and their more advanced bone age, and the incidence is higher among 
boys, in good correlation with their higher growth rate. Third, the metaphyses of the 
long bones of the extremities are the most frequent location, and they are also 
responsible for most longitudinal growth. Once the period of growth is achieved, the 
incidence of these tumors decreases and their anatomic distribution varies, with the long 
and flat bones being equally affected. Finally, this theory is supported by the association 
between these tumors and other diseases in which excessive cellular proliferation occurs 
(eg, Paget disease, benign fibrous lesions).1,3,4 
 
Fraumeni5 described that osteosarcoma and to a lesser extent Ewing sarcoma patients 
were significantly taller than patients diagnosed with other tumor types. Therefore, the 
origin of the bone tumors could be related to the increased susceptibility of the 
proliferative bone cells to oncogenic agents, mitotic errors, or chromosome aberrations 
during the growth spurt, thus cooperating in the neoplastic transformation. However, 
this hypothesis is not fully accepted. Multiple studies have been carried out to support 
the finding of increased height in bone cancer patients,6–9 but some of the authors did 
not find evidence of this association10–13 and others found opposite results.14 
 
Growth is a complex process, regulated by a net of environmental and genetic factors. It 
is well known that vitamin D is involved in skeletal metabolism: directly, regulating the 
proliferation, differentiation, and migration of osteoblasts and chondrocytes in the 
growth plates of the epiphysis and indirectly, regulating the homeostasis of calcium and 
phosphorus. In addition, vitamin D deficiency may induce a growth failure and/or bone 
metabolism alteration that can be evident even in the intrauterine and postnatal periods 
of life.15,16 
 
As a result, during the past few years, investigators have tested the association between 
the genotype for several polymorphisms within the vitamin D receptor (VDR) gene and 
growth parameters such as height, weight, and bone mineral density (BMD).17–19 
Minamitani et al20 analyzed the relationship between height and the genotype for the 
Fok I polymorphism of the VDR gene in the healthy Japanese population. They 
observed that heterozygotes (Ff) were significantly taller than homozygotes (FF or ff), 
and the frequency of the Ff genotype was significantly reduced among patients with 
constitutional short stature. Other studies have focused on the TaqI and Bsm I VDR 
polymorphisms and their association with height or weight at birth, during the first 
years of life, and during adolescence.17–19 Other genes involved in growth and skeletal 
maturation are the estrogen receptor (ER) gene, which determines growth during the 
postnatal and pubertal periods,21,22 as suggested by the association between the allelic 
variants of this gene and height, weight, and the expression of the VDR gene. The 
collagen Iα1  (COLIα1 ) gene is also considered a good candidate, given that it is the 
main component of the bone matrix.23,24 
 
Our hypothesis was that children with bone sarcoma would be taller at diagnosis than 
the reference population of Spanish children, and that this could be influenced by the 
presence ofpolymorphisms in genes involved in bone metabolism. Therefore, our 
objectives were to compare height at diagnosis of osteosarcoma and Ewing sarcoma 
with that of the reference children according to sex and age; to analyze the frequency of 
the genotypes for the polymorphisms of the VDR, ER, and COLIα1  genes in patients 
and in healthy controls; and to test the relationship between genetic markers and height 
in our patients. 
 
 
 
PATIENTS AND METHODS 
 
Subjects 
 
We included 72 Spanish children with osteosarcoma and 53 Spanish children with 
Ewing sarcoma who were treated and followed at the Department of Pediatrics of the 
University Clinic of Navarra, Spain, from 1984 to 2000 using standard protocols.25,26 
This investigation was approved by the Ethics Committee of the University Hospital, 
and informed consent was obtained from all participants or their parents. Patients with a 
family history of cancer, bone disease, or endocrine alterations were excluded from the 
analysis. 
 
The mean age of the patients at diagnosis was 14.10 (4.01) years for those with 
osteosarcoma and 13.30 (4.30) years for those with Ewing sarcoma. Sex distribution 
was 46% girls and 54% boys for osteosarcoma and 41% girls and 59% boys for Ewing 
sarcoma. 
 
 
Anthropometric Analysis 
 
Fourteen osteosarcoma and 17 Ewing sarcoma patients were excluded from the 
anthropometric study because their data were obtained in other hospitals. Height 
(Harpenden stadiometer, Holtain Ltd., UK), weight (electronic scale), and body mass 
index (BMI, weight [kg]/height [m2]) were measured at diagnosis for 58 osteosarcoma 
and 36 Ewing sarcoma patients and retrospectively obtained from the medical records. 
The data were compared with the standards published for the Spanish children 
according to age and sex27 and expressed as standard deviation scores (SDS). All the 
patients considered for the analysis had a normal stage of development for their age 
according to Tanner.28 
 
Genetic Analysis 
 
We included 72 osteosarcoma patients and 53 Ewing sarcoma patients from whom 
DNA was available and a control group of 143 healthy Spanish children (49% girls and 
51% boys) with a mean age of 16.60 (6.10) years. The polymorphisms for the restriction 
endonucleases Fok I,20 Apa I, and TaqI of the VDR gene,29 XbaI and Pvu II of the ER 
gene,30 and Msc I of the COLIα1  gene31 were characterized by polymerase chain 
reaction (PCR) amplification and restriction fragment length polymorphism (RFLP) 
analysis. The alleles for the genetic markers were represented in uppercase or lowercase 
if the restriction sites were absent or present, respectively. 
 
 
Statistical Analysis 
 
The height, weight, and BMI data of osteosarcoma and Ewing sarcoma patients, 
expressed as SDS, fulfilled the normality criteria and were described as mean (standard 
deviation [SD]). Their comparison to the standards published for the Spanish reference 
children27 was done by the Student t test. Height (in cm) was described as median 
(interquartile range [IQR]) given the non-normal distribution of the variable. For the 
comparison of the genotypes, the Pearson chi-square test was used. The relationship 
between height-SDS of patients and their genotypes was analyzed by analysis of 
variance with multiple post hoc comparisons (Student-Newman-Keuls). Differences 
were considered statistically significant if their associated probability was P ≤ 0.05. The 
statistical analysis was performed using the Statistical Package for the Social Sciences 
program, version 10.0 (SPSS, Chicago, IL). 
  
 
  
RESULTS 
 
The mean age of the patients at diagnosis was 14.10 (4.01) years for those with 
osteosarcoma and 13.30 (4.30) years for those with Ewing sarcomas. At that time, all 
the patients had a normal Tanner development staging for their age. The age at 
diagnosis of most osteosarcoma and Ewing sarcoma patients coincided with the 
acceleration of the pubertal growth spurt reported for the standard Spanish reference 
children and was similar in boys and girls (Fig. 1). The age of peak growth velocity in 
Spanish reference children is 12 years for girls and 14 years for boys, and the age at 
diagnosis for our patients was 13.81 (4.31) and 14.11 (3.95) for boys and girls with 
osteosarcoma and 12.36 (3.94) and 13.93 (4.97) for boys and girls with Ewing sarcoma. 
 
The location of the primary tumors was femur (41.7%), tibia (40.3%), humerus (5.6%), 
and fibula (5.6%) for osteosarcomas and femur (13.7%), tibia (21.6%), flat bones 
(25.5%), and extraosseous (21.6%) for Ewing sarcomas. We did not detect any 
differences in the age of presentation between the tumors in the humerus with respect to 
those of the femur or tibia. The distribution of the tumors within the long bones, 
concerning their distal or proximal portions, was as follows: distal metaphysis of the 
femur (87.5% for osteosarcoma, 60% for Ewing sarcoma), proximal tibia (68.2% and 
55.6%), and proximal humerus (100% and 66.7%). 
 
Both osteosarcoma (P < 0.001) and Ewing sarcoma (P = 0.013) patients were 
significantly taller at diagnosis than the Spanish reference children (Table 1). If we 
considered both sexes independently, the differences remained except for boys with 
Ewing sarcoma. With regard to weight, only osteosarcoma patients were significantly 
heavier than the reference children. The BMI did not differ significantly between either 
of the tumor types and the reference population. 
 
The allele frequencies for all the polymorphisms analyzed were in Hardy-Weinberg 
equilibrium in the control population. The distribution of the genotypes for the Fok I 
marker of the VDR gene was significantly different in osteosarcoma patients compared 
with healthy controls (Table 2), with the Ff genotype being overrepresented among 
patients with osteosarcoma (P = 0.048) but not among those with Ewing sarcoma. The 
odds ratio for this genotype was 1.78 (1.00–3.16), with an increased relative risk of 78% 
for heterozygous Ff carriers. We did not detect any other outstanding association 
between any of the polymorphic markers analyzed and the development of 
osteosarcoma or Ewing sarcoma. 
 
Height and weight at diagnosis among Ewing sarcoma patients were significantly 
different depending on the genotype for the Fok I marker of the VDR gene in such a 
way that Ff heterozygotes were statistically shorter and thinner at diagnosis than any of 
the homozygotes (FF and ff) (P = 0.013) (Fig. 2). This difference was also evident if 
both sexes were considered independently. We did not detect any association between 
height and weight at diagnosis of bone sarcoma and the genotype for the Apa I and TaqI 
polymorphisms of the VDR gene or for those of the ER and COLIα1  genes. We 
observed a highly significant association (P < 0.001) between the alleles A for Apa I 
and t for TaqI markers of the VDR gene and between alleles P-X and p-x for Pvu II and 
XbaI markers of the ER gene, which confirms the presence of a strong linkage 
disequilibrium between these markers. 
 
 
 
DISCUSSION 
 
The relationship between the development of bone tumors during infancy and growth 
acceleration continues to be controversial. The fact that the incidence of bone sarcomas 
peaks during childhood and adolescence suggests that the etiologic mechanism of these 
tumors must be present during this period. The difference in presentation between boys 
and girls and the location of these tumors support the hypothesis that the bone growth 
rate that is characteristic of this age may be involved.1,3,4 Although Ewing sarcoma is of 
neural origin and therefore presents several clinical differences compared with 
osteosarcoma, this fact does not seem to influence its epide-miologic characteristics.9,32
  
Since Fraumeni5 demonstrated that patients with osteosarcoma and Ewing sarcoma 
were taller than other cancer patients, and that this could be related to the increase in the 
growth rate, multiple papers have been published, some supporting and others 
disagreeing with this hypothesis. Our data, along with those of others,3–5 confirm the 
preferential localization of these bone tumors for the long bones of the extremities, at 
the metaphyseal portions of the most rapidly growing bones in adolescents, as well as 
the peak ofpresentation during adolescence, overlapping with the growth spurt. 
Other studies6–8 that show an association between the development of bone tumors and 
high stature are based on the measurement of height at the time of diagnosis, but lack 
any previous data on growth before that time. Growth is not a linear process but rather 
is characterized by frequent, intense, and short spurts or increases in its velocity that 
seem to be determinant of final height.33 A short-term evaluation of growth previous to 
the diagnosis would possibly yield more precise information. 
 
In this sense, Gelberg et al9 described the height of bone cancer patients 1 year before 
diagnosis; they observed that at that time they were already taller than the control group 
regardless of the stage and age ofpubertal development and height at birth. Given the 
retrospective nature of our study design, we lacked data concerning previous 
anthropometric measurements or parental height. Other authors have not shown 
discrepancies in height or in the growth rate during the 3 years before diagnosis of this 
kind of tumor.10–13 
 
Our Ewing sarcoma patients did not show significant differences in terms of weight at 
diagnosis, even though they were taller than the healthy controls. This could be related 
to the constitutional syndrome that these patients show at diagnosis and that is due to 
the prolonged period from tumor development to diagnosis if the location of the primary 
tumor is either central or extraosseous. On the contrary, the peripheral location of most 
primary osteosarcomas allows a rapid diagnosis. 
 
All of the investigations noted were retrospective and have several limitations.8,9,11–13 
First, the collection of data was usually done using medical or school records, which 
introduces differences in measurement techniques, mistakes in data, and even 
“decreases” in height, or using questionnaires to parents, in which lack of memory may 
influence the results. Second, the reference population considered was not always sex- 
and age-matched to the patient group. Third, the interindividual variability at the 
initiation of the growth spurt and its duration and intensity makes the interpretation of 
the results difficult. Finally, the contradictory results may be explained by differences in 
sample size or the statistical analysis performed. 
 
We detected a significantly increased frequency of the heterozygous Ff genotype for the 
Fok I polymorphism of the VDR gene among our osteosarcoma patients that had not 
been previously described in the Spanish population.34 Given that these patients are 
significantly taller than the reference population and that this genotype has been 
associated with taller height,20 one would expect that Ff osteosarcoma patients would be 
taller than FF and ff patients, but this association could be not be confirmed in our 
series. The reason could be that all osteosarcoma patients are taller than the reference 
population, irrespective of their genotype, which may interfere with the detection of 
differences among genotypes that have been described in the healthy population with 
height within the normal range. Further, Ewing sarcoma patients who carried the Ff 
genotype had a significantly lower height than homozygous FF or ff patients. 
Nevertheless, the limited number of patients analyzed in this study does not allow us to 
draw definitive conclusions regarding this apparent contradiction. On the other hand, we 
observed that homozygous ff patients with osteosarcoma and Ewing sarcoma tended to 
have the highest height, which has also been described by Minamitani et al.20 
Nevertheless, the fact that the Ff genotype was overrepresented in this group of 
significantly tall patients and was associated with an odds ratio of 1.78 suggests a 
putative involvement of the Fok I genotype in growth. 
We did not detect any outstanding association between height at diagnosis and the 
genotype for the TaqI polymorphism of the VDR gene or the genotype for the ER and 
COLIα1 genes. Nevertheless, the findings reported by other authors seem contradictory 
and do not follow a common pattern.16–19,21–24 The differences in these results may be 
due to different reasons: there may be environmental factors that interact with the VDR 
locus accounting for functional differences among different genotypes, as has been 
described to happen with the effect of vitamin D and bone response and calcium 
resorption.35,36 The polymorphisms of the VDR gene may be linked to other genes that 
are also involved in growth and skeletal metabolism, in such a way that the degree of 
linkage could vary among different populations and provoke the appearance of different 
phenotypes.17,18 Finally, the association between alleles A (Apa I) and t (TaqI) of the 
VDR gene and alleles P-X andp-x for polymorphisms Pvu II and XbaI of the ER gene 
found in our series confirms the strong linkage disequilibrium that has already been 
reported.22,37 
 
In conclusion, children with osteosarcoma and those with Ewing sarcoma are 
significantly taller at diagnosis than a reference population. It seems that the Fok I 
polymorphism of the VDR gene may be involved in growth and final height in this 
group of children. To date, we lack longitudinal analysis of individual growth, height, 
and pubertal development of these patients, as well as the genes involved in the skeletal 
metabolism of children with bone cancer. 
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Figure 1. Comparison of the growth velocity curves according to Spanish reference 
children27 with the histograms of age at diagnosis in patients with osteosarcoma and 
Ewing sarcoma. 
 
 
 
 
 
 
Figure 2. Relationship between height at diagnosis27 and the genotype for the Fok I 
polymorphism of the VDR gene in osteosarcoma and Ewing sarcoma patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. VDR, ER, COLIα1 Genotype Distribution 
Polymorphism Gene Genotype Osteosarcoma (n = 72) (%) 
Ewing Sarcoma 
(n = 53) (%) 
Controls 
(n = 143) (%) 
Fok I VDR FF 31.9 32.1 36.4 
  Ff 59.8 49 45.4 
  ff 8.3 18.9 18.2 
Apa I VDR AA 26.8 32.1 32.2 
  Aa 45 50.9 46.8 
  aa 28.2 17 21 
Taq I VDR TT 43.7 34 37.1 
  Tt 40.8 43.4 44 
  tt 15.5 22.6 18.9 
Pvu II ER PP 25.4 20.7 28 
  Pp 53.5 47.2 46.1 
  pp 21.1 32.1 25.9 
Xba I ER XX 15.5 13.2 20.4 
  Xx 52.1 45.3 43.7 
  xx 32.4 41.5 35.9 
Msc I COLIα1 MM 55.6 73.6 60.1 
  Mm 33.3 18.9 32.9 
  mm 11.1 7.5 7 
 
 
 
 
 
 
 
